N-(heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamides for TRPV1 antagonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds for TRPV1 receptor antagonism do not effectively address the need for potent and specific antagonists with broad therapeutic applications, particularly in medicinal contexts.
Innovation Solution
Development of N-(heteroaryl)-1-heteroarylalkyl-1 H-indole-2-carboxamides, which exhibit antagonistic activity for TRPV1 receptors, characterized by specific structural formulas and synthesis processes, enabling their use in pharmaceutical compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing carboxamide compounds are used for TRPV1 receptor antagonism, then some antagonistic activity is achieved, but the activity is not potent or specific enough for broad therapeutic applications
Solution Approach 1:
The patent applies parameter changes by systematically modifying molecular structure parameters of carboxamide compounds. Specifically, it varies the heteroaryl groups (Y) at different positions, adjusts the heterocycle A substitutions, and modifies the W fused bicyclic group configurations to optimize TRPV1 receptor binding affinity and specificity, thereby achieving potent and reliable antagonistic activity suitable for broad therapeutic applications
2Reliability
If new compound structures are developed to improve antagonistic activity, then potency and specificity increase, but the complexity of synthesis and characterization increases
Solution Approach 1:
The patent applies segmentation by dividing the complex molecule into distinct functional modules: the core indole-2-carboxamide structure, the heteroaryl group Y, the heterocycle A, and the fused bicyclic group W. Each module can be independently synthesized and characterized, then assembled to create the final compound. This modular approach maintains high potency while managing synthesis complexity through systematic variation of individual segments
Solution Approach 2:
The patent applies universality by designing a core carboxamide structure that serves multiple therapeutic purposes. The general formula (I) framework can accommodate various heteroaryl and heterocyclic substitutions to target TRPV1 receptor for different therapeutic indications including pain management, inflammatory conditions, and other disorders, making the synthesis platform universally applicable across multiple therapeutic areas
Data Source
AI summary
The invention concerns compounds of general formula (I) wherein: X1, X2, X3, X4 represent, independently of one another, a hydrogen or halogen atom or a C1-C6-alkyl, C3-C7-cycloalkyl, C3-C7-cycloalkyl-C1-C3-alkylene, C1-C6-fluoroalkyl, C1-C6-alkoxyl, C1-C6-fluoroalkoxyl, cyano, C(O)NR1R2, nitro, NR1R2, C1-C6-thioalkyl, -S(O)-C1-C6-alkyl, -S(O)2-C1-C6-alkyl, SO2NR1R2, NR3COR4, NR3SO2R5 or aryl group, the aryl being optionally substituted; W represents a fused bicyclic group of formula (II) bound to the nitrogen atom by positions 1, 2, 3 or 4; A represents a five- or seven-membered heterocycle comprising from one to three heteroatoms selected among O, S or N; the carbon atom(s) of A being optionally substituted; n is equal to 1, 2 or 3; Y represents an optionally substituted heteroaryl; in base or acid addition salt form, as well as in hydrate or solvate form. The invention also concerns a method for preparing said compounds and their therapeutic use.